{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:32:27Z","timestamp":1793892747382,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,11,20]]},"DOI":"10.1038\/s41416-026-03583-y","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:13:03Z","timestamp":1787829183000},"page":"1649-1656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["On-treatment core needle biopsy identifies early responders for axillary surgery de-escalation: results from a prospective cohort"],"prefix":"10.1038","volume":"135","author":[{"given":"Yifan","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajia","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5464-4395","authenticated-orcid":false,"given":"Guangyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"3583_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. Breast cancer, version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22:331\u201357.","journal-title":"J Natl Compr Canc Netw"},{"key":"3583_CR2","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1200\/JCO.2006.07.4062","volume":"25","author":"A Lucci","year":"2007","unstructured":"Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25:3657\u201363.","journal-title":"J Clin Oncol"},{"key":"3583_CR3","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S1470-2045(18)30380-2","volume":"19","author":"V Galimberti","year":"2018","unstructured":"Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1385\u201393.","journal-title":"Lancet Oncol"},{"key":"3583_CR4","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810\u201321.","journal-title":"N Engl J Med"},{"key":"3583_CR5","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/S1470-2045(21)00122-4","volume":"22","author":"JM P\u00e9rez-Garc\u00eda","year":"2021","unstructured":"P\u00e9rez-Garc\u00eda JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P, et al. Chemotherapy de-escalation using an (18)F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol. 2021;22:858\u201371.","journal-title":"Lancet Oncol"},{"key":"3583_CR6","doi-asserted-by":"publisher","first-page":"e210891","DOI":"10.1001\/jamasurg.2021.0891","volume":"156","author":"S Samiei","year":"2021","unstructured":"Samiei S, Simons JM, Engelen SME, Beets-Tan RGH, Classe JM, Smidt ML. Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis. JAMA Surg. 2021;156:e210891.","journal-title":"JAMA Surg"},{"key":"3583_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/jamaoncol.2016.4163","volume":"3","author":"M Pilewskie","year":"2017","unstructured":"Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol. 2017;3:549\u201355.","journal-title":"JAMA Oncol"},{"key":"3583_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamasurg.2017.0562","volume":"152","author":"AB Tadros","year":"2017","unstructured":"Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg. 2017;152:665\u201370.","journal-title":"JAMA Surg"},{"key":"3583_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.annonc.2019.10.012","volume":"31","author":"J Heil","year":"2020","unstructured":"Heil J, Kuerer HM, Pfob A, Rauch G, Sinn HP, Golatta M, et al. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. Ann Oncol. 2020;31:61\u201371.","journal-title":"Ann Oncol"},{"key":"3583_CR10","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/jamasurg.2018.2696","volume":"153","author":"AU Barron","year":"2018","unstructured":"Barron AU, Hoskin TL, Day CN, Hwang ES, Kuerer HM, Boughey JC. Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg. 2018;153:1120\u20136.","journal-title":"JAMA Surg"},{"key":"3583_CR11","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/SLA.0000000000003126","volume":"271","author":"S Samiei","year":"2020","unstructured":"Samiei S, van Nijnatten TJA, de Munck L, Keymeulen K, Simons JM, Kooreman LFS, et al. Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy. Ann Surg. 2020;271:574\u201380.","journal-title":"Ann Surg"},{"key":"3583_CR12","doi-asserted-by":"crossref","unstructured":"Alamoodi M U, Wazir K, Mokbel, Patani N, Varghese J, and K Mokbel. Omitting sentinel lymph node biopsy after neoadjuvant systemic therapy for clinically node negative HER2 positive and triple negative breast cancer: a pooled analysis. Cancers, 2024;15.","DOI":"10.3390\/cancers15133325"},{"key":"3583_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(24)00104-9","volume":"25","author":"A van der Voort","year":"2024","unstructured":"van der Voort A, Louis FM, van Ramshorst MS, Kessels R, Mandjes IA, Kemper I, et al. MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2024;25:603\u201313.","journal-title":"Lancet Oncol"},{"key":"3583_CR14","doi-asserted-by":"publisher","first-page":"686591","DOI":"10.3389\/fonc.2021.686591","volume":"11","author":"Y Xie","year":"2021","unstructured":"Xie Y, Wu S, Zhang Y, Li J, Mo M, Shao Z, et al. Optimal duration of neoadjuvant taxane and carboplatin combined with anti-HER2 targeted therapy for HER2-positive breast cancer. Front Oncol. 2021;11:686591.","journal-title":"Front Oncol"},{"key":"3583_CR15","doi-asserted-by":"publisher","first-page":"e626","DOI":"10.1634\/theoncologist.2019-0583","volume":"25","author":"S Wu","year":"2020","unstructured":"Wu S, Wang Y, Li J, Zhang N, Mo M, Klimberg S, et al. Subtype-guided (18) F-FDG PET\/CT in tailoring axillary surgery among patients with node-positive breast cancer treated with neoadjuvant chemotherapy: a feasibility study. Oncologist. 2020;25:e626\u2013e633.","journal-title":"Oncologist"},{"key":"3583_CR16","unstructured":"Association, T.S.o.B.C.C.A.-C. and B.O.G.o.t.O.B.o.t.C.M. Association, Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2026 edition) %J China Oncology. 2025.35:1157-255."},{"key":"3583_CR17","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1200\/JCO-25-00099","volume":"43","author":"KU Park","year":"2025","unstructured":"Park KU, Somerfield MR, Anne N, Brackstone M, Conlin AK, Couto HL, et al. Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2025;43:1720\u201341.","journal-title":"J Clin Oncol"},{"key":"3583_CR18","doi-asserted-by":"publisher","first-page":"e204103","DOI":"10.1001\/jamasurg.2020.4103","volume":"155","author":"MK Tasoulis","year":"2020","unstructured":"Tasoulis MK, Lee HB, Yang W, Pope R, Krishnamurthy S, Kim SY, et al. Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict residual cancer. JAMA Surg. 2020;155:e204103.","journal-title":"JAMA Surg"},{"key":"3583_CR19","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1200\/JCO.21.02439","volume":"40","author":"A Pfob","year":"2022","unstructured":"Pfob A, Sidey-Gibbons C, Rauch G, Thomas B, Schaefgen B, Kuemmel S, et al. Intelligent vacuum-assisted biopsy to identify breast cancer patients with pathologic complete response (ypT0 and ypN0) after neoadjuvant systemic treatment for omission of breast and axillary surgery. J Clin Oncol. 2022;40:1903\u201315.","journal-title":"J Clin Oncol"},{"key":"3583_CR20","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1148\/radiol.2018180273","volume":"289","author":"SC Partridge","year":"2018","unstructured":"Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, et al. Diffusion-weighted MRI findings predict pathologic response in neoadjuvant treatment of breast cancer: the ACRIN 6698 multicenter trial. Radiology. 2018;289:618\u201327.","journal-title":"Radiology"},{"key":"3583_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/bjs\/znac391","volume":"110","author":"EMC Rossi","year":"2023","unstructured":"Rossi EMC, Invento A, Pesapane F, Pagan E, Bagnardi V, Fusco N, et al. Diagnostic performance of image-guided vacuum-assisted breast biopsy after neoadjuvant therapy for breast cancer: prospective pilot study. Br J Surg. 2023;110:217\u201324.","journal-title":"Br J Surg"},{"key":"3583_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1148\/radiol.2019190014","volume":"293","author":"R Kim","year":"2019","unstructured":"Kim R, Chang JM, Lee HB, Lee SH, Kim SY, Kim ES, et al. Predicting axillary response to neoadjuvant chemotherapy: breast MRI and US in patients with node-positive breast cancer. Radiology. 2019;293:49\u201357.","journal-title":"Radiology"},{"key":"3583_CR23","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1002\/ijc.33495","volume":"148","author":"M Graeser","year":"2021","unstructured":"Graeser M, Schrading S, Gluz O, Strobel K, W\u00fcrstlein R, K\u00fcmmel S, et al. Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: combined analysis from the WSG ADAPT subtrials. Int J Cancer. 2021;148:2614\u201327.","journal-title":"Int J Cancer"},{"key":"3583_CR24","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1148\/radiol.2017170180","volume":"285","author":"AM Fowler","year":"2017","unstructured":"Fowler AM, Mankoff DA, Joe BN. Imaging neoadjuvant therapy response in breast cancer. Radiology. 2017;285:358\u201375.","journal-title":"Radiology"},{"key":"3583_CR25","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/bjs.12026","volume":"108","author":"MEM van der Noordaa","year":"2021","unstructured":"van der Noordaa MEM, van Duijnhoven FH, Cuijpers FNE, van Werkhoven E, Wiersma TG, Elkhuizen PHM, et al. Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer. Br J Surg. 2021;108:667\u201374.","journal-title":"Br J Surg"},{"key":"3583_CR26","first-page":"1863","volume":"109","author":"SY Wu","year":"2023","unstructured":"Wu SY, Li JW, Wang YJ, Jin KR, Yang BL, Li JJ, et al. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study. Int J Surg. 2023;109:1863\u201370.","journal-title":"Int J Surg"},{"key":"3583_CR27","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072\u20138.","journal-title":"J Clin Oncol"},{"key":"3583_CR28","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1097\/SLA.0000000000004572","volume":"276","author":"S Kuemmel","year":"2022","unstructured":"Kuemmel S, Heil J, Rueland A, Seiberling C, Harrach H, Schindowski D, et al. A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients. Ann Surg. 2022;276:e553\u2013e562.","journal-title":"Ann Surg"},{"key":"3583_CR29","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1200\/JCO.21.00934","volume":"39","author":"M Brackstone","year":"2021","unstructured":"Brackstone M, Baldassarre FG, Perera FE, Cil T, Chavez Mac Gregor M, Dayes IS, et al. Management of the axilla in early-stage breast cancer: Ontario health (Cancer Care Ontario) and ASCO Guideline. J Clin Oncol. 2021;39:3056\u201382.","journal-title":"J Clin Oncol"},{"key":"3583_CR30","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/SLA.0000000000000558","volume":"261","author":"M Donker","year":"2015","unstructured":"Donker M, Straver ME, Wesseling J, Loo CE, Schot M, Drukker CA, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015;261:378\u201382.","journal-title":"Ann Surg"},{"key":"3583_CR31","first-page":"LBA509","volume":"42","author":"JL Meisel","year":"2024","unstructured":"Meisel JL, Khoury K, Chien AJ, Wallace AM, Arora M, Rozenblit M, et al. Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato). Results I-SPY2 2 trial. 2024;42:LBA509\u2013LBA509.","journal-title":"Results I-SPY2 2 trial"},{"key":"3583_CR32","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jamaoncol.2015.4935","volume":"2","author":"SS Mougalian","year":"2016","unstructured":"Mougalian SS, Hernandez M, Lei X, Lynch S, Kuerer HM, Symmans WF, et al. Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. JAMA Oncol. 2016;2:508\u201316.","journal-title":"JAMA Oncol"},{"key":"3583_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/bjs.11963","volume":"108","author":"L Zetterlund","year":"2021","unstructured":"Zetterlund L, Celebioglu F, Hatschek T, Frisell J, de Boniface J. Long-term prognosis in breast cancer is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status. Br J Surg. 2021;108:583\u20139.","journal-title":"Br J Surg"},{"key":"3583_CR34","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.ejca.2010.12.009","volume":"47","author":"N Saxena","year":"2011","unstructured":"Saxena N, Hartman M, Aziz R, Rapiti E, Bhoo Pathy N, Lim SE, et al. Prognostic value of axillary lymph node status after neoadjuvant chemotherapy. Results from a multicentre study. Eur J Cancer. 2011;47:1186\u201392.","journal-title":"Eur J Cancer"},{"key":"3583_CR35","first-page":"LBA506","volume":"41","author":"J Cortes","year":"2023","unstructured":"Cortes J, P\u00e9rez-Garc\u00eda JM, Ruiz-Borrego M, Stradella A, Bermejo B, Escriv\u00e1-de-Roman\u00ed S, et al. 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC). JAMA Oncol. 2023;41:LBA506\u2013LBA506.","journal-title":"JAMA Oncol"},{"key":"3583_CR36","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617\u201328.","journal-title":"N Engl J Med"},{"key":"3583_CR37","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147\u201359.","journal-title":"N Engl J Med"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03583-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03583-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03583-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:53:14Z","timestamp":1793890394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03583-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,11,20]]}},"alternative-id":["3583"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03583-y","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All the procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}